Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Stryker is a leading global medical technology company with a broad portfolio in orthopaedics and other medical specialties. Operations are segregated into two reportable segments: Orthopaedic Implants (reconstructive, trauma, spinal, craniomaxillofacial) and MedSurg Equipment (surgical, navigation, endoscopic, patient handling). The company also provides outpatient physical therapy services.
Key Financial Metrics (2006)
| Metric | 2006 (in millions) | 2005 (in millions) | Change |
|---|---|---|---|
| Net Sales | $5,405.6 | $4,871.5 | +11% |
| Gross Profit | $3,556.9 | $3,153.0 | +13% |
| Gross Margin | 65.8% | 64.7% | +110 bps |
| Operating Income | $1,074.3 | $950.1 | +13% |
| Net Earnings | $777.7 | $643.6 | +21% |
| Diluted EPS | $1.89 | $1.57 | +20% |
| Operating Cash Flow | $867.3 | $833.4 | +4% |
| Capital Expenditures | $217.5 | $271.7 | -20% |
| Long-Term Debt | $0.0 | $184.2 | Repaid |
| Current Ratio | 2.6 | 2.3 | Improved |
Liquidity: Cash and cash equivalents totaled $416.6 million, with marketable securities of $998.2 million. Working capital increased to $2,182.8 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales grew 11% driven by a 10% increase in unit volume/mix and 1% price increase. Orthopaedic Implants sales rose 9%, while MedSurg Equipment sales surged 16%.
- Acquisition Charges: A $52.7 million charge for purchased in-process research and development (IPR&D) was recorded in Q1 2006 related to the acquisition of Sightline Technologies (flexible endoscopes). This compares to a $15.9 million IPR&D charge in 2005 for PlasmaSol.
- Debt Reduction: The company repaid all long-term debt, reducing the balance from $231.6 million in 2005 to $14.8 million (current maturities only) in 2006.
- Accounting Changes: Adoption of FASB Statement No. 123(R) increased stock-based compensation expense, reducing operating income by $56.2 million. Adoption of FASB Statement No. 158 recognized a $22.8 million pension liability on the balance sheet.
- Segment Performance: Orthopaedic Implants remained the largest segment (57% of sales), but MedSurg Equipment grew faster (16% vs 9%).
Guidance, Outlook, and Risks
2007 Outlook:
- Earnings: Projected diluted net earnings per share of approximately $2.42 (28% increase over 2006 reported EPS).
- Sales: Anticipated constant currency net sales increase of 11% to 13%.
- Currency Impact: Expected favorable impact of 0% to 1% on full-year net sales if exchange rates hold near current levels.
Key Risks and Contingencies:
- Regulatory Approvals: Future results depend on FDA approval for OP-1 Putty (spinal fusion), FlexiCore/CerviCore (artificial discs), and Sightline/PlasmaSol technologies. Delays could impact growth.
- Legal Investigations: The company is cooperating with Department of Justice investigations regarding billing practices (Physiotherapy Associates), consulting contracts with surgeons, and potential antitrust violations in orthopaedic implants.
- Reimbursement Pressure: Pricing pressures and cost-containment measures in the U.S., Japan, and other markets could adversely affect demand and pricing.
- Inventory: Days sales in inventory increased to 122 days (from 114 in 2005) due to stocking for new product launches.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and commercial success of Sightline (endoscopes) and PlasmaSol (sterilization) technologies, given the $52.7 million write-off and lack of immediate revenue contribution.
- OP-1 Regulatory Status: Monitor FDA review status for the OP-1 Putty PMA application for posterolateral lumbar spine fusion, a key growth driver.
- Legal Exposure: Track developments in the DOJ investigations regarding antitrust and billing practices to assess potential settlement costs or reputational damage.
- Inventory Levels: Watch for potential write-downs if the increased inventory (122 days) does not convert to sales as anticipated.
- Debt Capacity: Note the company has $1,028.1 million in available borrowing capacity under credit facilities, providing flexibility for future M&A.